Home Cart 0 Sign in  

[ CAS No. 107-35-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 107-35-7
Chemical Structure| 107-35-7
Structure of 107-35-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 107-35-7 ]

Related Doc. of [ 107-35-7 ]

Alternatived Products of [ 107-35-7 ]

Product Details of [ 107-35-7 ]

CAS No. :107-35-7 MDL No. :MFCD00008197
Formula : C2H7NO3S Boiling Point : -
Linear Structure Formula :- InChI Key :XOAAWQZATWQOTB-UHFFFAOYSA-N
M.W : 125.15 Pubchem ID :1123
Synonyms :
2-Aminoethanesulfonic acid;β-Aminoethylsulfonic Acid;β-Aminoethylsulfonic Acid, NSC 32428, Taurine;NSC 32428

Calculated chemistry of [ 107-35-7 ]

Physicochemical Properties

Num. heavy atoms : 7
Num. arom. heavy atoms : 0
Fraction Csp3 : 1.0
Num. rotatable bonds : 2
Num. H-bond acceptors : 4.0
Num. H-bond donors : 2.0
Molar Refractivity : 24.97
TPSA : 88.77 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -9.98 cm/s

Lipophilicity

Log Po/w (iLOGP) : -0.28
Log Po/w (XLOGP3) : -4.11
Log Po/w (WLOGP) : -0.09
Log Po/w (MLOGP) : -1.51
Log Po/w (SILICOS-IT) : -1.18
Consensus Log Po/w : -1.43

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 3.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : 2.11
Solubility : 16000.0 mg/ml ; 127.0 mol/l
Class : Highly soluble
Log S (Ali) : 2.85
Solubility : 88500.0 mg/ml ; 707.0 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : 0.36
Solubility : 288.0 mg/ml ; 2.3 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.17

Safety of [ 107-35-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 107-35-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 107-35-7 ]
  • Downstream synthetic route of [ 107-35-7 ]

[ 107-35-7 ] Synthesis Path-Upstream   1~7

  • 1
  • [ 85-44-9 ]
  • [ 107-35-7 ]
  • [ 4403-36-5 ]
YieldReaction ConditionsOperation in experiment
34% With phosphorus pentachloride; potassium acetate In water; acetic acid; toluene Preparation 82
2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-ethanesulfonyl chloride
A suspension of taurine (8.0 g, 63.9 mmol) and potassium acetate (6.7 g, 68.3 mmol) in acetic acid was refluxed for 15 min.
Phthalic anhydride (10.1 g, 68.4 mmol) was added and the solution was refluxed for 3 h.
The reaction was cooled to room temperature and the solid was filtered off, washed with cold acetic acid and dried under vacuum at 100° C. to give a white solid.
The solid (14.3 g, 54.7 mmol) was suspended in toluene (50 ml) and phosphorus pentachloride (8.12 g, 39.0 mmol) was added under nitrogen.
The reaction mixture was heated under reflux for 1 h.
Further phosphorus pentachloride (8.12 g, 39.0 mmol) was added and the reaction mixture was refluxed for 2.5 h.
The brownish solution was decanted from the small amount of solid formed and then concentrated in vacuo, the residue was poured onto ice:water (50:50, lOOmIl) and filtered.
The solid was dried for 16 h in vacuo at 45° C. to give a pale brown solid (6.4 g, 34percent).
Reference: [1] Patent: US6313312, 2001, B1,
[2] Archiv der Pharmazie, 2007, vol. 340, # 12, p. 656 - 660
[3] Journal of Medicinal Chemistry, 2010, vol. 53, # 6, p. 2390 - 2400
[4] European Journal of Medicinal Chemistry, 2018, vol. 146, p. 108 - 122
  • 2
  • [ 107-35-7 ]
  • [ 196505-69-8 ]
  • [ 516-35-8 ]
Reference: [1] Patent: CN102718829, 2016, B, . Location in patent: Paragraph 0033-0041
  • 3
  • [ 107-35-7 ]
  • [ 128-13-2 ]
  • [ 516-35-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 1996, vol. 4, # 6, p. 885 - 890
  • 4
  • [ 107-35-7 ]
  • [ 83-44-3 ]
  • [ 1180-95-6 ]
Reference: [1] Organic and Biomolecular Chemistry, 2012, vol. 10, # 20, p. 4109 - 4115
  • 5
  • [ 107-35-7 ]
  • [ 128-13-2 ]
  • [ 35807-85-3 ]
Reference: [1] Organic and Biomolecular Chemistry, 2012, vol. 10, # 20, p. 4109 - 4115
  • 6
  • [ 107-35-7 ]
  • [ 81-25-4 ]
  • [ 145-42-6 ]
Reference: [1] Organic and Biomolecular Chemistry, 2012, vol. 10, # 20, p. 4109 - 4115
  • 7
  • [ 107-35-7 ]
  • [ 64491-70-9 ]
  • [ 157791-21-4 ]
YieldReaction ConditionsOperation in experiment
10% With sodium hydroxide In methanol at 50℃; for 21.25 h; Synthesis 15-1 -A; (f?)-2-(Methoxymethyl)morpholine; A solution of (R)-(~) glycidylmethylether (0.800 g, 10.66 mmol) in methanol (11 mL) was added dropwise to a solution of 2-aminoethanesulfonic acid (6.440 g, 53.3 mmol) in 40percent aqueous sodium hydroxide (11 mL) at 5O0C. After stirring for 75 minutes, further 40percent aqueous sodium hydroxide (19 mL) was added and the reaction mixture was stirred for 20 hours at 5O0C. The solution was cooled to room temperature and diluted with water (76 mL). The aqueous phase was extracted with ethyl acetate (3 x 75 mL). The combined organic phases were dried (Na2SO4). The solvent was removed in vacuo and <n="108"/>the crude mixture was purified by flash chromatography on silica, eluting with ethyl acetate-hexane (2:8), to give the title compound as a colourless oil (0.121 g, 10percent).1H NMR (500 MHz1 (CD3)2CO) 2.47 (1 H, dd, J = 10.4, 1.9), 2.70-2.72 (1H, m), 2.84 (1 H1 dd, J = 11.9, 2.2), 3.22-3.25 (2H, m), 3.27 (3H, s), 3.29-3.34 (4H, m), 3.45-3.53 (2H, m), 3.73 (1H, dt, J = 11.0, 2.5).
Reference: [1] Patent: WO2008/75007, 2008, A1, . Location in patent: Page/Page column 106-107
Same Skeleton Products
Historical Records